Metformin for obesity in children and adolescents: a systematic review.

Park, MH; Kinra, S; Ward, KJ; White, B; Viner, RM; (2009) Metformin for obesity in children and adolescents: a systematic review. Diabetes care, 32 (9). pp. 1743-5. ISSN 0149-5992 DOI:

Text - Published Version

Download (343kB) | Preview


OBJECTIVE: To summarize the efficacy of metformin in reducing BMI and cardiometabolic risk in obese children and adolescents without diabetes. RESEARCH DESIGN AND METHODS: We performed a systematic review and meta-analysis of randomized controlled trials (RCTs). Double-blind RCTs of > or =6 months duration in obese subjects age < or =19 years without diabetes were included. Our primary outcomes of interest include changes in BMI and measures of insulin sensitivity. RESULTS: Five trials met inclusion criteria (n = 320 individuals). Compared with placebo, metformin reduced BMI by 1.42 kg/m(2) (95% CI 0.83-2.02) and homeostasis model assessment insulin of resistance (HOMA-IR) score by 2.01 (95% CI 0.75-3.26). CONCLUSIONS: Metformin appears to be moderately efficacious in reducing BMI and insulin resistance in hyperinsulinemic obese children and adolescents in the short term. Larger, longer-term studies in different populations are needed to establish its role in the treatment of overweight children.

Item Type: Article
Faculty and Department: Faculty of Epidemiology and Population Health > Dept of Non-Communicable Disease Epidemiology
Faculty of Public Health and Policy > Dept of Health Services Research and Policy
Research Centre: Centre for Global Non-Communicable Diseases (NCDs)
PubMed ID: 19502540
Web of Science ID: 269687100035


Download activity - last 12 months
Downloads since deposit
Accesses by country - last 12 months
Accesses by referrer - last 12 months
Impact and interest
Additional statistics for this record are available via IRStats2

Actions (login required)

Edit Item Edit Item